secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cencora, Inc. (COR)
CIK:        0001140859
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0001104659-24-097135
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Cencora raises FY2024 adjusted EPS guidance to $13.60-$13.70; extends Evernorth supply deal through 2029
--------------------------------------------------------------------------------

- Adjusted diluted EPS for FY2024 raised to $13.60-$13.70 from prior $13.55-$13.65.
- FY2025 adjusted operating income and EPS growth expected at bottom of long-term targets (5-8% and 8-12%).
- FY2025 headwinds include COVID products and potential June 2025 loss of an oncology customer after its pending acquisition.
- Extended pharmaceutical supply agreement with Evernorth Health Services for three additional years through September 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1140859/000110465924097135/0001104659-24-097135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1140859/000110465924097135/tm2423361d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-097135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer